<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02462174</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00008718/ NF</org_study_id>
    <nct_id>NCT02462174</nct_id>
  </id_info>
  <brief_title>Topical Ketamine Versus Caudal Ketamine for Postoperative Analgesia in Children Undergoing Inguinal Herniotomy</brief_title>
  <acronym>TKversusCK</acronym>
  <official_title>Caudal Epidural Block Versus Topical Ketamine Application for Postoperative Pain Relief After Elective Inguinal Herniotomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To find alternatives to caudal analgesia that could be more safe and effective and to
      demonstrate the analgesic efficacy of topical ketamine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The most commonly performed inguinal surgeries in children include inguinal hernia repair
      with or without orchidopexy (orchiopexy). Eighty children aged 6 months to 6 yr of ASA
      physical status I or II, undergoing elective unilateral inguinal herniotomy will be included.
      In caudal group, patients will receive a mixture of 0.5 mg/ kg ketamine in 1 ml/kg
      bupivacaine 0.25% (maximum volume = 20 ml) by caudal route after anesthesia and before start
      of surgery. In topical group, at the end of the procedure, after identification and ligation
      of the hernial sac, a mixture of 0.5 mg/ kg ketamine in 0.3 ml/kg bupivacaine 0.25% will be
      sprayed around the spermatic cord and upon the ilioinguinal nerve in a fan shaped manner by
      the surgeon. The primary outcome measure will be the time to first request for analgesia.
      Secondary outcome measures will include the number of analgesic doses required in the first
      24 h postoperative, pain scores, sensory and motor block, agitation scores, parent
      satisfaction and adverse effects in the first 48h postoperative.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>time to first request for postoperative analgesia</measure>
    <time_frame>48 hours postoperative</time_frame>
    <description>time in hours from admission to PACU till first request for analgesia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>total consumption of postoperative analgesics</measure>
    <time_frame>48 hours postoperative</time_frame>
    <description>the amount of analgesic drugs in mg given in the first 48h postoperative</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Children's Hospital of Eastern Ontario Pain Scale (CHEOPS, 0-10) pain score</measure>
    <time_frame>180 minutes postoperative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Faces Legs Activity Cry Consolability tool (FLACC, 0-10).</measure>
    <time_frame>180 minutes postoperative.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the agitation score (0= child is asleep, 1= awake/calm, 2= irritable/ consolable cry, 3=inconsolable cry, 4= the child is agitating and thrashing and restlessness).</measure>
    <time_frame>60 minutes postoperative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>parent's satisfaction on a four-point Likert scale (1, excellent; 2, good; 3, fair; 4, poor).</measure>
    <time_frame>48 hours postoperative</time_frame>
    <description>the score will be recorded once at the end of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>noninvasive blood pressure</measure>
    <time_frame>Intra-operative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>heart rate</measure>
    <time_frame>Intra-operative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Verbal Numeric Rating Scale (VNRS)</measure>
    <time_frame>48 hours postoperative</time_frame>
    <description>the pain score will be assessed at frequent intervals in the 1st 48 h postoperative</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>Topical ketamine and topical bupivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.5 mg/ kg ketamine in 0.3 ml/kg bupivacaine 0.25% (maximum volume = 20 ml) administered directly around the spermatic cord in the wound after end of surgery and before closure of the wound.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Caudal ketamine and caudal bupivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.5 mg/ kg ketamine in 1 ml/kg bupivacaine 0.25% (maximum volume = 20 ml) administered by caudal epidural route after anesthesia and before the start of surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>0.5 mg/ kg ketamine with bupivacaine by caudal route after anesthesia and before start of surgery.</description>
    <arm_group_label>Topical ketamine and topical bupivacaine</arm_group_label>
    <other_name>Katalar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>0.5 mg/ kg ketamine with bupivacaine will be sprayed around the spermatic cord before wound closure.</description>
    <arm_group_label>Caudal ketamine and caudal bupivacaine</arm_group_label>
    <other_name>Katalar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>1 ml/kg bupivacaine 0.25% (maximum volume = 20 ml) by caudal route</description>
    <arm_group_label>Topical ketamine and topical bupivacaine</arm_group_label>
    <other_name>bucaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>0.3 ml/kg bupivacaine 0.25% will be sprayed around the spermatic cord before wound closure</description>
    <arm_group_label>Caudal ketamine and caudal bupivacaine</arm_group_label>
    <other_name>bucaine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. age (6 months to 6 years)

          2. ASA physical status I or II.

          3. Operation: elective unilateral inguinal herniotomy.

        Exclusion Criteria:

          1. A history of developmental delay or mental retardation,

          2. Known or suspected coagulopathy,

          3. Known allergy to any local anaesthetic,

          4. Known congenital anomaly of the spine or signs of spinal anomaly,

          5. Infection at the sacral region.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hala S Abdel-Ghaffar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assisstant professor in Anesthesia and intensive care department, faculty of medicine, Assiut university, Egypt</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Assiut university hospitals</name>
      <address>
        <city>Assiut</city>
        <state>Assiut governorate</state>
        <zip>715715</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 29, 2015</study_first_submitted>
  <study_first_submitted_qc>June 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2015</study_first_posted>
  <last_update_submitted>October 1, 2015</last_update_submitted>
  <last_update_submitted_qc>October 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Hala Saad Abdel-Ghaffar</investigator_full_name>
    <investigator_title>assistant professor anesthesia and intensive care department/ faculty of medicine/ Assiut university/ Egypt.</investigator_title>
  </responsible_party>
  <keyword>anesthesia</keyword>
  <keyword>analgesia</keyword>
  <keyword>caudal</keyword>
  <keyword>ketamine</keyword>
  <keyword>bupivacaine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

